Discover novel immune checkpoint targets

Retrogenix has identified several novel immune checkpoint targets that are now the focus for the development of exciting new immunotherapies.

Identifying new immunotherapy targets provides significant commercial value for our clients as well as pd-1-pd-l1-immune-checkpointuncovering the mechanisms of action that broadens our overall understanding of how cancer cells avoid triggering an immune response.

Cancer can evade immune detection by ‘switching off’ T-cells through inhibitory ligand-receptor interactions at immune checkpoints. Antibodies or recombinant forms of receptors or ligands that disrupt these interactions can stimulate very effective anti-tumour responses. Recent discoveries in this area have significantly expanded the range of therapies that are being developed for patients, with the ultimate aim of conferring long-term immunity to cancer.

Retrogenix’s results are included in multiple patent applications that have been made by our study sponsors in order to protect the valuable intellectual property that has arisen from these key discoveries. As many important immune checkpoint interactions are still yet to be fully characterised we continue to work extensively in this area. Our case studies below demonstrate how the cell microarray technology is used to identify immune checkpoint targets with a high degree of specificity.

Contact us to discuss an immune checkpoint project with a member of our science team.


Compugen study identifies key TIGIT family immune checkpoint pair

Data presented at the 2016 Annual Meeting of the Society for the Immunotherapy of Cancer (SITC) showcased the utility of the Retrogenix platform in identifying a key immune checkpoint pairing within the TIGIT family. This case study provides details of how PVRL2 was identified as a specific cell surface binding partner for PVRIG which has presented new opportunities for the development of cancer immunotherapy treatments including potential combination therapies with current immune checkpoint blockers.

Read the case study

Using the Retrogenix technology to uncover immune checkpoint receptors

Retrogenix screening is an efficient method for rapidly identifying specific ligand-receptor binding in human cells. Here we demonstrate the power of the approach in uncovering immune checkpoint interactions using the ligands CTLA4 and CD27 (results presented at PEGS Boston).


Read the case study

Talk to us about a project
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
Capella Bioscience Logo
Sanofi Logo
Unum Theraputics Logo
Celyad Logo
Thank you again for your professionalism, for a fine analysis, and for our enjoyable scientific exchanges.
Professor Gunnar Lindahl, Lund University, Sweden